{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:36Z","timestamp":1788844236427,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) remains severely underdiagnosed in China due to the absence of newborn screening, limited sweat chloride testing capacity, and low clinical awareness. Diagnostic delay results in irreversible lung damage and precludes timely genotype-directed therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>\n                      A 16-year-old Chinese boy presented with end-stage CF lung disease after a 15-year diagnostic odyssey. He had recurrent lower respiratory tract infections since infancy, progressive bronchiectasis, CF-associated liver disease with portal hypertension, and chronic\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      \/Burkholderia cepacia co-infection. Sweat chloride was 102\u00a0mmol\/L. Whole-exome sequencing identified compound heterozygous CFTR variants: c.579 + 1_579+2insACAT (a canonical splice-site insertion, predicted null) inherited from the father, and c.1766 + 5G&amp;gt;T (CF-causing in CFTR2, near-complete exon 13 skipping) inherited from the mother. Fecal elastase was preserved (525\u00a0\u03bcg\/g), confirming pancreatic sufficiency; this finding is consistent with but does not prove residual CFTR function. CFTR modulator therapy was unavailable. He died of cardiopulmonary failure approximately 1\u00a0year after diagnosis while awaiting lung transplantation. Cascade testing confirmed the same genotype in his 11-year-old sister (sweat chloride 111\u00a0mmol\/L), who also died of cardiopulmonary failure within months. Their eldest brother had died at age two of severe pneumonia without CF being suspected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This family illustrates the convergence of three pharmacologically relevant barriers in underserved CF populations: prolonged diagnostic delay precluding specialized care, uncharacterized population-specific variants lacking theratyping data, and inaccessibility of CFTR modulators. The preserved pancreatic function despite end-stage lung disease is compatible with residual CFTR activity, but the contribution of either allele and potential responsiveness to CFTR modulators require transcript, protein, and functional characterization. This underscores the urgent need for systematic theratyping of under-characterized CFTR variants reported in East Asian populations. Expansion of sweat chloride testing, clinician education, and international collaborative theratyping efforts are needed to break this cycle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1894322","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:32Z","timestamp":1788841592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report end-stage cystic fibrosis with fatal outcome in two siblings from a Chinese family: a 15-year diagnostic odyssey"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuelin","family":"Shen","sequence":"first","affiliation":[{"name":"Respiratory Department, National Clinical Research Center for Respiratory Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qionghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Respiratory Department, Quanzhou Maternal and Child Health Hospital (Quanzhou Children\u2019s Hospital)","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Yang","sequence":"additional","affiliation":[{"name":"Respiratory Department, National Clinical Research Center for Respiratory Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3760\/cma.j.cn112147-20221214-00971","article-title":"Bronchiectasis-china. [chinese experts consensus statement: diagnosis and treatment of cystic fibrosis]","volume":"46","year":"2023","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B3","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13023-024-03506-1","article-title":"Diagnosing cystic fibrosis in low- and middle-income countries: challenges and strategies","volume":"19","author":"Fuhrer","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"00109","DOI":"10.1183\/23120541.00109-2017","article-title":"Early diagnosis from newborn screening maximises survival in severe cystic fibrosis","volume":"4","author":"Padoan","year":"2018","journal-title":"ERJ Open Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jmg-2022-108501","article-title":"Genetic spectrum of Chinese children with cystic fibrosis: comprehensive data analysis from the main referral centre in China","volume":"60","author":"Shen","year":"2022","journal-title":"J. Med. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"148190","DOI":"10.1016\/j.gene.2024.148190","article-title":"Genetic analysis and functional study of novel CFTR variants in Chinese children with cystic fibrosis","volume":"907","author":"Sun","year":"2024","journal-title":"Gene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1399-0004.1995.tb03944.x","article-title":"Skipping of exon 12 as a consequence of a point mutation in the cystic fibrosis transmembrane conductance regulator gene found in a consanguineous Chinese family","volume":"47","author":"Zielenski","year":"1995","journal-title":"Clin. Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:34Z","timestamp":1788841594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":13,"alternative-id":["10.3389\/fphar.2026.1894322"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1894322","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1894322"}}